Based in Hyderabad, Sri Krishna Pharma specialises in the bulk manufacture of many first line of defence drugs, from APIs to DC granules, and now a range of finished dosage forms.
Sri Krishna Pharmaceuticals Ltd (SKPL), established in 1974, started life as a pioneer in the bulk manufacture of acetaminophen (Paracetamol) for the domestic Indian market. Today, the company is a vertically integrated bulk manufacturer of multiple first-line-of-defence APIs, PFIs and finished dosage drugs. Paracetamol is still very important to the company and the company remains one of the largest manufacturers in the world. The role of Indian bulk drug manufacturers in the global pharma supply chain has evolved greatly, with SKPL increasing its presence in the synthesis of bulk APIs, direct compression, intermediate and finished dosage products.
To meet the growing demands of our long-standing customers, we have established five manufacturing facilities with each plant producing dedicated specialist products. These facilities are equipped with ever-evolving modern equipment to ensure the processing of the final critical steps of the required drug substances is compliant. Our facilities are audited against critical GMP standards and have numerous ongoing certifications, including USFDA, EDQM, COFEPRIS, ANVISA, GHA, AIFA and ANSM.
In the area of API granules, the company is an approved supplier of Paracetamol, Ibuprofen, Metformin, Aspirin, Furosemide and Methocarbamol. We are also a major supplier of folic acid in various products at our Shamshabad facility.
Sustained investment in technology and human capital enhances our backward and forward integration from KSM to finished dosage. Our expertise extends from manufacturing APIs, direct compression (DC) to premixes. Delivering compliant and quality products that offer great value and flexibility have been a winning formula for SKPL.
Communication with clients is something the company takes immense pride in. The values of transparency, trust and dedication have been guiding principles since our inception and are now part of our ‘Keep it Simple’ approach. We maintain these values have enabled us to create, sustain and grow relationships for almost 50 years, with our partner customers worldwide.
It’s our belief to consistently grow and maintain any momentum you need collaboration, innovation and a clear set of ethical policies which meet international standards. We continue to invest in our people and infrastructure in order to serve 60 plus global markets.
In R&D, we are currently focusing on research efforts in the field of biotechnology, through global collaborations. This is an extension of our ‘Keep it Simple’ philosophy but, in this case, trying to make a process easier or allowing value engineering to make something more accessible.
The simpler we can make something the more efficient and cost-effective it will be. Whether this is pure economics or a carbon-neutral effect, in most cases, the finished dosage products delivered to our customers allow them to serve the therapeutic more effectively. Notwithstanding this simple mantra, and adhering to the qualities and compliance in all that we manufacture, we are always seeking the most efficient value solution. Our partners understand our philosophy and frequently help us achieve better operations by endorsing the concept of continual improvement.
You might have the seed of an idea for cooperation or collaboration but are unsure of how to progress it and with what resources. No matter where you join us on our tree, from the roots to near the tips of the branches, you will receive a commitment to achieve value.